Design, Synthesis and Biological Evaluation of 4-Aryl-5,7-dihydro-6<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-6-one Derivatives as a PI3Kα Inhibitor-Reference-Cited by-同舟云学术

Design, Synthesis and Biological Evaluation of 4-Aryl-5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one Derivatives as a PI3Kα Inhibitor

Published:2019-06-01 Issue:6 Volume:42 Page:1013-1018
ISSN:0918-6158
Container-title:Biological and Pharmaceutical Bulletin
language:en
Short-container-title:Biol. Pharm. Bull.

Author:

Hu Shengquan¹,Zhao Zhichang¹,Ni Yeming²,Xin Hongxing³,Yan Hong¹,Song Xiuqing¹

Affiliation:

1. Beijing Key Laboratory of Environmental and Viral Oncology, College of Life Science and Bio-engineering, Beijing University of Technology

2. Fan Gongxiu Honors College, Beijing University of Technology

3. Jumpcan Pharmaceutical Group Company Limited

Publisher

Pharmaceutical Society of Japan

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

https://www.jstage.jst.go.jp/article/bpb/42/6/42_b19-00080/_pdf

Reference27 articles.

1. 1) Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, Yan H, Gazdar A, Powell SM, Riggins GJ, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Velculescu VE. High frequency of mutations of the PIK3CA gene in human cancers. Science, 304, 554 (2004).

2. 2) Bader AG, Kang S, Zhao L, Vogt PK. Oncogenic PI3K deregulates transcription and translation. Nat. Rev. Cancer, 5, 921–929 (2005).

3. 3) Liu P, Cheng H, Roberts TM, Zhao JJ. Targeting the phosphoinositide 3-kinase pathway in cancer. Nat. Rev. Drug Discov., 8, 627–644 (2009).

4. 4) Fan YH, Li W, Liu DD, Bai MX, Song HR, Xu YN, Lee S, Zhou ZP, Wang J, Ding HW. Design, synthesis, and biological evaluation of novel 3-substituted imidazo[1,2-a]pyridine and quinazolin-4(3H)-one derivatives as PI3Kα inhibitors. Eur. J. Med. Chem., 139, 95–106 (2017).

5. 5) Mayer IA, Arteaga CL. The PI3K/AKT pathway as a target for cancer treatment. Annu. Rev. Med., 67, 11–28 (2016).

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in Small-Molecule Dual Inhibitors Targeting EGFR and HER2 Receptors as Anti-Cancer Agents;Current Medicinal Chemistry;2024-06-10

2. Synthesis and biological evaluation of N 4 ‐hydrazone derivatives of 5,7‐dihydro‐6 H ‐pyrrolo[2,3‐ d ]pyrimidin‐6‐one as novel anticancer agents with antimetastatic adjunct efficacy;Archiv der Pharmazie;2021-08-08

3. Structural Aspects of mTOR Inhibitors: In Progress to Search Potential Compounds;Anti-Cancer Agents in Medicinal Chemistry;2021-07-20

4. Discovery and optimization of 5,7-dihydro-6H-pyrrolo[2,3-d]pyrimidin-6-one derivatives as mTORC1/mTORC2 dual inhibitors;Bioorganic Chemistry;2019-11